481 related articles for article (PubMed ID: 24184032)
1. Preparation and evaluation of once-daily sustained-release coated tablets of tolterodine-L-tartrate.
Pradhan R; Kim YI; Chang SW; Kim JO
Int J Pharm; 2014 Jan; 460(1-2):205-11. PubMed ID: 24184032
[TBL] [Abstract][Full Text] [Related]
2. A formulation approach for development of HPMC-based sustained release tablets for tolterodine tartrate with a low release variation.
Cao QR; Choi JS; Liu Y; Xu WJ; Yang M; Lee BJ; Cui JH
Drug Dev Ind Pharm; 2013 Nov; 39(11):1720-30. PubMed ID: 23062115
[TBL] [Abstract][Full Text] [Related]
3. Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder.
Sun F; Sui C; Zhou Y; Liu X; Shi Y; Wu Y; Li Y
Int J Pharm; 2013 Sep; 454(1):532-8. PubMed ID: 23891744
[TBL] [Abstract][Full Text] [Related]
4. In vitro release of ketoprofen from hydrophilic matrix tablets containing cellulose polymer mixtures.
Vueba ML; Batista de Carvalho LA; Veiga F; Sousa JJ; Pina ME
Drug Dev Ind Pharm; 2013 Nov; 39(11):1651-62. PubMed ID: 23094867
[TBL] [Abstract][Full Text] [Related]
5. Studies on the preparation, characterization and pharmacological evaluation of tolterodine PLGA microspheres.
Sun F; Sui C; Teng L; Liu X; Teng L; Meng Q; Li Y
Int J Pharm; 2010 Sep; 397(1-2):44-9. PubMed ID: 20600717
[TBL] [Abstract][Full Text] [Related]
6. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine.
Olsson B; Szamosi J
Clin Pharmacokinet; 2001; 40(3):227-35. PubMed ID: 11327200
[TBL] [Abstract][Full Text] [Related]
7. Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder.
Olsson B; Szamosi J
Clin Pharmacokinet; 2001; 40(2):135-43. PubMed ID: 11286323
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effect of iontophoresis and chemical enhancers on transdermal permeation of tolterodine tartrate for the treatment of overactive bladder.
Prasanthi D; Lakshmi PK
Int Braz J Urol; 2013; 39(1):63-75; discussion 76. PubMed ID: 23489517
[TBL] [Abstract][Full Text] [Related]
9. Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin.
Sathyan G; Dmochowski RR; Appell RA; Guo C; Gupta SK
Clin Pharmacokinet; 2004; 43(14):1059-68. PubMed ID: 15530134
[TBL] [Abstract][Full Text] [Related]
10. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine.
Dmochowski R; Chen A; Sathyan G; MacDiarmid S; Gidwani S; Gupta S
J Clin Pharmacol; 2005 Aug; 45(8):961-8. PubMed ID: 16027408
[TBL] [Abstract][Full Text] [Related]
11. Subcoating with Kollidon VA 64 as water barrier in a new combined native dextran/HPMC-cetyl alcohol controlled release tablet.
Castellanos Gil E; Iraizoz Colarte A; Lara Sampedro JL; Bataille B
Eur J Pharm Biopharm; 2008 May; 69(1):303-11. PubMed ID: 18053697
[TBL] [Abstract][Full Text] [Related]
12. Effects of manufacturing process variables on in vitro dissolution characteristics of extended-release tablets formulated with hydroxypropyl methylcellulose.
Huang Y; Khanvilkar KH; Moore AD; Hilliard-Lott M
Drug Dev Ind Pharm; 2003 Jan; 29(1):79-88. PubMed ID: 12602495
[TBL] [Abstract][Full Text] [Related]
13. Drug release and swelling kinetics of directly compressed glipizide sustained-release matrices: establishment of level A IVIVC.
Sankalia JM; Sankalia MG; Mashru RC
J Control Release; 2008 Jul; 129(1):49-58. PubMed ID: 18456362
[TBL] [Abstract][Full Text] [Related]
14. Compression of coated drug beads for sustained release tablet of glipizide: formulation, and dissolution.
Nguyen C; Christensen JM; Ayres JW
Pharm Dev Technol; 2014 Feb; 19(1):10-20. PubMed ID: 23259589
[TBL] [Abstract][Full Text] [Related]
15. Influence of hydroxypropyl methylcellulose mixture, apparent viscosity, and tablet hardness on drug release using a 2(3) full factorial design.
Khanvilkar KH; Huang Y; Moore AD
Drug Dev Ind Pharm; 2002 May; 28(5):601-8. PubMed ID: 12098849
[TBL] [Abstract][Full Text] [Related]
16. A novel approach to sustained pseudoephedrine release: differentially coated mini-tablets in HPMC capsules.
Ishida M; Abe K; Hashizume M; Kawamura M
Int J Pharm; 2008 Jul; 359(1-2):46-52. PubMed ID: 18467046
[TBL] [Abstract][Full Text] [Related]
17. Preparation, in vitro, preclinical and clinical evaluations of once daily sustained release tablets of aceclofenac.
Mutalik S; Naha A; Usha AN; Ranjith AK; Musmade P; Manoj K; Anju P; Prasanna S
Arch Pharm Res; 2007 Feb; 30(2):222-34. PubMed ID: 17366745
[TBL] [Abstract][Full Text] [Related]
18. [Optimization of the formulation of ranolazine hydrochloride sustained-release tablet and its pharmacokinetics in dogs].
Li CJ; Yu YL; Yang QM; Li Y; Zhang YH; Wang JY
Yao Xue Xue Bao; 2010 Sep; 45(9):1170-6. PubMed ID: 21351575
[TBL] [Abstract][Full Text] [Related]
19. Controlled-release carbamazepine matrix granules and tablets comprising lipophilic and hydrophilic components.
Barakat NS; Elbagory IM; Almurshedi AS
Drug Deliv; 2009 Jan; 16(1):57-65. PubMed ID: 19555310
[TBL] [Abstract][Full Text] [Related]
20. Role of cellulose ether polymers on ibuprofen release from matrix tablets.
Vueba ML; Batista de Carvalho LA; Veiga F; Sousa JJ; Pina ME
Drug Dev Ind Pharm; 2005 Aug; 31(7):653-65. PubMed ID: 16207613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
